

# TUMOR

# IMMUNOLOGY

ChemPartner offers a broad array of *in vitro* assays and *in vivo* models to fast-forward your immuno-oncology drug discovery.

## IMMUNE-MODULATING TARGET

### ANTIBODY APPROACH

### SMALL MOLECULE APPROACH

#### Antibody Generation

- Hybridoma
- Phage display
- Hlg transgenic mice

#### Compound Generation

- Chemical synthesis
- MedChem

#### Lead Identification

- Binding assays
- Target specific assays

#### Compound Pool

- Target specific assays: enzyme, cell-based
- *In vitro* assays

#### Lead Optimization

- Humanization
- Affinity maturation

#### Early Leads

- Syngeneic models
- Combination therapies
- *Ex vivo* analysis

#### Lead Characterization

- MLR and other hPBMC assays
- *In vivo* efficacy (humanized mouse model, hTg KI mice)

#### Lead(s)



- hPBMC assays
- Antigen specificity

#### Candidate


#### Candidate

Surrogate Abs  
Cross-reactive Abs

# MIXED LYMPHOCYTE REACTION MLR ASSAY



# TUMOR CELL & T CELL CO-CULTURE ASSAY



# IN VITRO TUMOR IMMUNOLOGY ASSAYS

# IN VIVO TUMOR IMMUNOLOGY MODELS

With over 20 well-characterized syngeneic models and humanized mouse models, we offer our customers a complete pharmacology solution – the case study shown here is an example of how ‘hidden value’ of a targeted therapy was uncovered employing our platform:

